Table 1.
Patient characteristics
| Arm A (tomuzotuximab), n = 117 | Arm B (cetuximab), n = 123 | |
|---|---|---|
| Age, years | 59.8 | 59.8 |
| Sex, n (%) | ||
| Female | 18 (15.4) | 17 (13.8) |
| Male | 99 (84.6) | 106 (86.2) |
| Eastern Cooperative Oncology Group, n (%) | ||
| 0 | 22 (18.8) | 26 (22) |
| 1 | 95 (81.2) | 96 (78) |
| Smoking status, n (%) | ||
| Nonsmoker | 20 (17.1) | 19 (15.4) |
| Former smoker | 71 (60.7) | 77 (62.6) |
| Active smoker | 26 (22.2) | 27 (22) |
| Primary tumor localization, n (%) | ||
| Oral cavity | 37 (31.6) | 38 (30.9) |
| Oropharynx | 41 (35) | 46 (37.4) |
| Hypopharynx | 13 (11.1) | 15 (12.2) |
| Larynx | 18 (15.4) | 17 (13.8) |
| Other | 8 (6.8) | 7 (5.7) |
| Disease status, n (%) | ||
| Locally recurrent | 52 (44.4) | 57 (46.3) |
| Metastatic | 65 (55.6) | 66 (53.7) |
| p16 status, n (%) | ||
| Positive | 17 (14.5) | 15 (12.2) |
| Negative | 91 (77.8) | 104 (84.6) |
| Missing | 9 (7.7) | 4 (3.2) |
| FcγRIII allotype, n (%) | ||
| FF | 44 (37.6) | 48 (39) |
| FV | 55 (47) | 56 (45.5) |
| VV | 18 (15.4) | 19 (15.4) |
| Epidermal growth factor receptor, n (%) | ||
| Treatment naïve | 106 (90.6) | 114 (92.7) |
| Pretreated as part of multimodality treatment | 11 (9.4) | 9 (7.3) |